Achieve Life Sciences raises $16.5M in pursuit of anti-smoking drug

Achieve Life Sciences (Achieve), a Bothell-based biotech company, has raised nearly $16.5 million. According to the company, the funding was secured through a registered direct offering, and the funding will be deployed to support product development, regulatory activities, working capital and general corporate purposes.


Achieve is developing a plant-based smoking cessation treatment called cytisinicline to help people quit smoking through reducing withdrawal symptoms and the feeling of satisfaction with smoking.


“We are confident that cytisinicline has the potential to help the millions of people who are battling nicotine dependence,” said John Bencich, Chief Executive Officer.


READ THE STORY at Puget Sound Business Journal»